Decentralized Manufacturing for Cell Therapy

Memo

Advance Scalability, Accessibility and Affordability of Autologous Cell Therapies As the cell therapy space bears witness to an increasing number of autologous therapies gaining regulatory approval, the essential role of the manufacturing ecosystem has never been clearer. It is business critical for cell therapy drug developers to have a robust strategy for scale up whilst overcoming the labour and cost intensive nature of batch manufacturing to reduce the cost of goods. Enter the timely arrival of the inaugural Decentralized Manufacturing for Cell Therapy Summit, the pioneering forum for cell therapy leaders across manufacturing to gain practical insights into the strategic adoption of decentralized manufactured cell therapy products in order to reduce manufacturing turnaround time and overcome commercial patient access barriers. Download Full Event Guide - https://ter.li/4h61g8 Register Now - https://ter.li/0pcz9y URLs:Tickets: https://go.evvnt.com/1975675-2?pid=5569 Brochure: https://go.evvnt.com/1975675-3?pid=5569  Date and Time: On Mon, 29 Jan 2024 09:00 - Wed, 31 Jan 2024 15:45 Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:Conference + 2 Workshops - Drug Developer Pricing: USD 4297.00,Conference + 1 Workshop - Drug Developer Pricing: USD 3648.00,Conference - Drug Developer Pricing: USD 2999.00,Conference + 2 Workshops - Academic and Research Institute Pricing: USD 3697.00,Conference + 1 Workshop - Academic and Research Institute Pricing: USD 3148.00,Conference Only - Academic and Research Institute Pricing: USD 2599.00,Conference + 2 Workshops - Service Provider Pricing: USD 5297.00,Conference + 1 Workshop - Service Provider Pricing: USD 4548.00,Conference Only - Service Provider Pricing: USD 3799.00 Speakers: Richard McFarland, Chief Regulatory Officer, Advanced Regenerative Manufacturing Institute, Scott Berger, Principal Consultant, Advanced Cell and Gene Therapy, Amish Patel, Vice President Technical Operations, Calidi Biotherapeutics, Michelle Andraza, Senior Director, Global Quality Assurance and CMC, Exuma Biotech, Chelsea (Chip) White Schneider, National Chair in Transportation and Logistics Professor, Georgia Institute of Technology, Chris Baldwin, Senior Director, Cell and Gene Therapy Supply Chain, GSK, Arya Pawar, Senior Associate, Oncology Cell Therapy and Manufacturing, ImmunityBio, Sumit Verma, Senior Vice President, Global Strategic Manufacturing, Iovance, Vaishali Shukla, Vice President, Quality Commercial Quality Manufacturing, Kite Pharma, Teresa Igler, Senior Manager, Manufacturing and Supply, Kyverna Therapeutics, Lara Ionescu, Silverman Principal Consultant, IS BioConsulting, Vladimir Slepushkin, CTO, MedTherapy Biotech, Nan Zhang, Chief Cell Therapy Manufacturing, NIH Clinical Center, Sumona Sarkar, Biomedical Engineer, National Institute of Standards and Technology, Yuguo Leo Lei, Assistant Professor, Penn State University, Steven Feldman, Site Head and Scientific Director and Laboratory for Cell and Gene Medicine, Stanford Medicine